Phase IIIb study of durvalumab plus platinum-etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Preliminary efficacy results

D. Isla,E. Arriola,M. R. Garcia Campelo,P. Diz Tain, C. Marti Blanco, M. M. Lopez-Brea Piqueras,A. L. Moreno Vega, L. A. Leon Mateos,J. M. Oramas Rodriguez,V. Gutierrez Calderon,M. Majem Tarruella,A. Sanchez Hernandez,C. Aguado de la Rosa,R. Alvarez Cabellos,J. L. Marti Ciriquian,A. Moreno Paul,J. L. Firvida Perez, A. Callejo Mellen, L. Baez, L. Paz-Ares

ANNALS OF ONCOLOGY（2022）

引用 0|浏览2

暂无评分

摘要

Most patients (Pts) with small-cell lung cancer (SCLC) have extensive-stage (ES) disease at diagnosis, and poor prognosis. First-line durvalumab (D) plus platinum–etoposide (EP) significantly improved overall survival in pts with ES-SCLC versus control group in CASPIAN study. CANTABRICO will assess safety and effectiveness of D plus EP in a real world ES-SCLC population in Spain.

查看译文

关键词

cell lung cancer,small cell lung cancer,lung cancer,durvalumab,platinum-etoposide,first-line,extensive-stage

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要